Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring. (3rd October 2019)

• Record Type: Journal Article
• Authors: Kobayashi, Kazuo; Toyoda, Masao; Kimura, Moritsugu; Hatori, Nobuo; Furuki, Takayuki; Sakai, Hiroyuki; Takihata, Masahiro; Umezono, Tomoya; Ito, Shun; Suzuki, Daisuke; Takeda, Hiroshi; Kanamori, Akira; Degawa, Hisakazu; Yamamoto, Hareaki; Machimura, Hideo; Mokubo, Atsuko; Chin, Keiichi; Obana, Mitsuo; Hishiki, Toshimasa; Aoyama, Kouta; Nakajima, Shinichi; Umezawa, Shinichi; Shimura, Hidetoshi; Aoyama, Togo; Sato, Kazuyoshi; Miyakawa, Masaaki
• Is Part Of: Clinical and experimental hypertension. Volume 41:Number 7(2019)
• Page Start: 637
• Page End: 644
• Publication Date: 2019-10-03
• Subjects: Sodium glucose co-transporter 2 inhibitors -- albumin-creatinine ratio -- chronic kidney disease -- home blood pressure monitoring -- masked hypertension; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.1080/10641963.2018.1529778
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: Decrease in blood pressure contributes to the reno-protective effects of sodium-glucose cotransporter 2 inhibitors; however, its relationship with home monitoring of blood pressure is unclear. We retrospectively analyzed 101 visiting members of the Kanagawa Physicians Association with type 2 diabetes mellitus and chronic kidney disease who were taking sodium-glucose cotransporter 2 inhibitors and who monitored blood pressure at home for a median treatment period of 14 months. At baseline, the mean value of HbA1c was 59.3 mmol/mol (7.6%) and the median value of albumin-creatinine ratio was 30.9 mg/gCr that was evaluated in 88 patients . The mean blood pressure both at office and home significantly decreased, and there was a significant positive correlation between the change in albumin–creatinine ratio and both blood pressures. Controlled hypertension, masked hypertension, white coat hypertension, and sustained hypertension were observed in 10.9%, 13.9%, 12.9%, and 62.4% of patients at the initiation of therapy, which changed to 10.9%, 16.8%, 17.8%, and 54.5% at the time of the survey, respectively. In conclusion, management of blood pressure both at office and home was found to be important for the reno-protective effects of sodium-glucose cotransporter 2 inhibitors along with strict blood pressure management.